Skip to content

Released Aug 11, 2025, before the open

10-Q filed Aug 11, 2025, 42 days after period end · 0001764013-25-000129

Q1 2026 · 10-Q
Revenue—
Net Income-$120.61MN/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.71N/M vs Q1 2025no prior Q4 2025 on file
Operating Cash Flow-$117,411,000N/M
Free Cash Flowderived-$117,411,000N/M

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Net Income-$120.61M-$87.15M-$73.94M-$40.37M
EPS Diluted-$0.71-$0.60-$0.57-$0.35

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR